MedPath

Moxifloxacin

Generic Name
Moxifloxacin
Brand Names
Avelox, Moxeza, Vigamox
Drug Type
Small Molecule
Chemical Formula
C21H24FN3O4
CAS Number
151096-09-2
Unique Ingredient Identifier
U188XYD42P
Background

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions
Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Clinical Trials
Related News

Intensified Short Course Regimen for TBM in Adults

Phase 3
Not yet recruiting
Conditions
Tuberculous Meningitis
Interventions
Drug: High dose rifampicin (25mg/kg)
Drug: HRZE
Drug: HRE
Drug: Steroid
First Posted Date
2023-06-23
Last Posted Date
2023-12-21
Lead Sponsor
Indian Council of Medical Research
Target Recruit Count
372
Registration Number
NCT05917340
Locations
🇮🇳

ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteer Study
Interventions
Drug: Bemnifosbuvir (BEM)
Drug: Placebo
First Posted Date
2023-06-15
Last Posted Date
2023-06-15
Lead Sponsor
Atea Pharmaceuticals, Inc.
Target Recruit Count
35
Registration Number
NCT05905484
Locations
🇨🇦

Atea Study Site, Québec, Montreal, Quebec, Canada

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2023-06-08
Last Posted Date
2025-04-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
107
Registration Number
NCT05893862
Locations
🇺🇸

California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0003), Glendale, California, United States

🇺🇸

Hassman Research Institute Marlton Site ( Site 0001), Marlton, New Jersey, United States

🇺🇸

NRC Research Institute ( Site 0004), Orange, California, United States

and more 1 locations

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: placebo
First Posted Date
2023-05-26
Last Posted Date
2024-12-06
Lead Sponsor
Pfizer
Target Recruit Count
43
Registration Number
NCT05878522
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

First Posted Date
2023-05-19
Last Posted Date
2023-07-14
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
56
Registration Number
NCT05867147
Locations
🇺🇸

Celerion - Tempe, Tempe, Arizona, United States

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

Phase 1
Completed
Conditions
QT/QTc
Interventions
Drug: Placebo
First Posted Date
2023-05-03
Last Posted Date
2023-06-09
Lead Sponsor
Emalex Biosciences Inc.
Target Recruit Count
29
Registration Number
NCT05841160
Locations
🇺🇸

PPD Austin Phase 1 Clinical Research Unit, Austin, Texas, United States

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Phase 1
Completed
Conditions
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Drug: CHF5993 Placebo
First Posted Date
2023-04-26
Last Posted Date
2023-10-31
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
95
Registration Number
NCT05830071
Locations
🇺🇸

PAREXEL Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

Phase 1
Completed
Conditions
Pain
Interventions
Drug: VX-548 Placebo
First Posted Date
2023-04-19
Last Posted Date
2024-03-20
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
72
Registration Number
NCT05818852
Locations
🇺🇸

ICON Lenexa, Lenexa, Kansas, United States

🇺🇸

ICON Salt Lake City, Salt Lake City, Utah, United States

PanACEA - STEP2C -01

Phase 2
Recruiting
Conditions
Other Specified Pulmonary Tuberculosis
Pulmonary Tuberculosis
Interventions
First Posted Date
2023-04-11
Last Posted Date
2024-04-17
Lead Sponsor
Michael Hoelscher
Target Recruit Count
270
Registration Number
NCT05807399
Locations
🇲🇼

Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi

🇹🇿

Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania

🇺🇬

Makerere University Lung Institute Limited, Kampala, Uganda

and more 5 locations

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

Phase 1
Completed
Conditions
Obesity
Interventions
Drug: Cagrilintide Placebo
First Posted Date
2023-04-07
Last Posted Date
2024-11-01
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
107
Registration Number
NCT05804162
Locations
🇩🇪

Parexel International GmbH, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy